Highlights ■ Accessibility to novel drugs for multiple myeloma render excellent outcomes. ■ Hemoglobin at diagnosis is a significant risk factor. ■ Age also impacts outcomes. ■ Hemoglobin and age-based model fared better than the International Staging System. ABSTRACT Objective: To report the outcomes of patients with multiple myeloma who had access to novel drugs in Brazil, and to establish a local benchmark. Methods: This prospective observational study was conducted at Hospital Israelita Albert Einstein in São Paulo, Brazil. We […]